Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy

Author： Petru Edgar

Publisher： Springer Publishing Company

ISSN： 0043-5341

Source： Wiener Medizinische Wochenschrift, Vol.158, Iss.5-6, 2008-03, pp. : 169-173

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT₃receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States

By Schwartzberg Lee Morrow Gary Balu Sanjeev Craver Chris Gayle Julie Cox David

Current Medical Research and Opinion, Vol. 27, Iss. 8, 2011-08 ,pp. : 1613-1622

Informa Healthcare

Access to resources Recommend Favorite

Comparative efficacy and tolerability of antiemetic prophylaxis for adult highly emetogenic chemotherapy: A network meta‐analysis of 143 randomized controlled trials

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 5, 2018-03 ,pp. : 1067-1076

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antiemetic Control with Palonosetron in Patients with Gastrointestinal Cancer Receiving a Fluoropyrimidine-Based Regimen in Addition to Either Irinotecan or Oxaliplatin: A Retrospective Study

Oncology, Vol. 83, Iss. 3, 2012-07 ,pp. : 135-140

Karger

Access to resources Recommend Favorite

EUROPEAN JOURNAL OF CANCER CARE (ELECTRONIC), Vol. 24, Iss. 5, 2015-09 ,pp. : 605-617

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Randomized Comparative Study of Antiemetic Prophylaxis with Ondansentron in a Single 32-mg Loading Dose versus 8 mg Every 6 h in Patients Undergoing Cisplatin-Based Chemotherapy

Oncology, Vol. 55, Iss. 6, 1998-10 ,pp. : 513-516

Karger

Access to resources Recommend Favorite